ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline

Area of Science:

• Neuroscience
• Gerontology
• Precision Medicine

Background:

• Alzheimer's disease (AD) is a leading cause of age-related cognitive decline with no effective cures.
• Current AD therapeutics offer limited, temporary symptomatic relief.
• A personalized, precision medicine approach is being explored for AD prevention and treatment.

Purpose of the Study:

• To assess the scalability of the ReCODE (reversal of cognitive decline) program.
• To determine if ReCODE can improve cognitive and metabolic function in individuals with subjective cognitive impairment, mild cognitive impairment, and early-stage AD.

Main Methods:

• 255 participants provided blood samples and completed cognitive assessments (MoCA).
• Participants engaged in the ReCODE program, receiving personalized consultations on diet, lifestyle, medications, and supplements.
• Cognitive and metabolic markers were tracked over 2-12 months, with pre- and post-treatment measures compared.

Main Results:

• Cognitive scores (MoCA) stabilized or improved in all participants.
• Metabolic risk factors, including blood glucose, hs-CRP, HOMA-IR, and vitamin D levels, showed significant improvement.
• While not as successful as a prior small trial, results surpassed anti-amyloid therapies.

Conclusions:

• A comprehensive, multi-factorial, personalized therapeutic program can mitigate AD risk factors.
• The ReCODE approach demonstrates potential for stabilizing or reversing cognitive decline.
• Further physician training may enhance the efficacy of this personalized therapeutic strategy.